Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action Article Swipe
Tomas G. Neilan
,
Mace L. Rothenberg
,
Laleh Amiri‐Kordestani
,
Ryan J. Sullivan
,
Richard M. Steingart
,
William W. Gregory
,
Hariharan Subramanian
,
Tarek A. Hammad
,
JoAnn Lindenfeld
,
Martin J. Murphy
,
Javid J. Moslehi
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1634/theoncologist.2018-0157
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1634/theoncologist.2018-0157
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for cancer. Due to the mechanism of action of ICIs, inflammatory reactions against normal tissue were an anticipated side effect of these agents; these immune-related adverse events have been documented and are typically low grade and manageable. Myocarditis has emerged as an uncommon but potentially life-threatening adverse reaction in patients treated with ICIs. Assessment and characterization of ICI-associated myocarditis is challenging because of its low incidence and protean manifestations. Nevertheless, the seriousness of ICI-associated myocarditis justifies a coordinated effort to increase awareness of this syndrome, identify patients who may be at risk, and enable early diagnosis and appropriate treatment. The “Checkpoint Inhibitor Safety Working Group,” a multidisciplinary committee of academic, industry, and regulatory partners, convened at a workshop hosted by Project Data Sphere, LLC, on December 15, 2017. This meeting aimed to evaluate the current information on ICI-associated myocarditis, determine methods to collect and share data on this adverse reaction, and establish task forces to close the identified knowledge gaps. In this report, we summarize the workshop findings and proposed steps to address the impact of ICI-associated myocarditis in patients with cancer.
Related Topics
Concepts
Myocarditis
Seriousness
Medicine
Adverse effect
Intensive care medicine
Ipilimumab
Immune checkpoint
Cancer
Internal medicine
Oncology
Immunotherapy
Political science
Law
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1634/theoncologist.2018-0157
- https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0157
- OA Status
- bronze
- Cited By
- 104
- References
- 47
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2803500132
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2803500132Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1634/theoncologist.2018-0157Digital Object Identifier
- Title
-
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to ActionWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-05-25Full publication date if available
- Authors
-
Tomas G. Neilan, Mace L. Rothenberg, Laleh Amiri‐Kordestani, Ryan J. Sullivan, Richard M. Steingart, William W. Gregory, Hariharan Subramanian, Tarek A. Hammad, JoAnn Lindenfeld, Martin J. Murphy, Javid J. MoslehiList of authors in order
- Landing page
-
https://doi.org/10.1634/theoncologist.2018-0157Publisher landing page
- PDF URL
-
https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0157Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0157Direct OA link when available
- Concepts
-
Myocarditis, Seriousness, Medicine, Adverse effect, Intensive care medicine, Ipilimumab, Immune checkpoint, Cancer, Internal medicine, Oncology, Immunotherapy, Political science, LawTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
104Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 4, 2024: 5, 2023: 9, 2022: 14, 2021: 26Per-year citation counts (last 5 years)
- References (count)
-
47Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2803500132 |
|---|---|
| doi | https://doi.org/10.1634/theoncologist.2018-0157 |
| ids.doi | https://doi.org/10.1634/theoncologist.2018-0157 |
| ids.mag | 2803500132 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/29802220 |
| ids.openalex | https://openalex.org/W2803500132 |
| fwci | 8.02515597 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D032921 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Consensus |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D006801 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Humans |
| mesh[2].qualifier_ui | Q000009 |
| mesh[2].descriptor_ui | D007167 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | adverse effects |
| mesh[2].descriptor_name | Immunotherapy |
| mesh[3].qualifier_ui | Q000139 |
| mesh[3].descriptor_ui | D009205 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | chemically induced |
| mesh[3].descriptor_name | Myocarditis |
| mesh[4].qualifier_ui | Q000473 |
| mesh[4].descriptor_ui | D009205 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | pathology |
| mesh[4].descriptor_name | Myocarditis |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D012307 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Risk Factors |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D032921 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Consensus |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D006801 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Humans |
| mesh[8].qualifier_ui | Q000009 |
| mesh[8].descriptor_ui | D007167 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | adverse effects |
| mesh[8].descriptor_name | Immunotherapy |
| mesh[9].qualifier_ui | Q000139 |
| mesh[9].descriptor_ui | D009205 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | chemically induced |
| mesh[9].descriptor_name | Myocarditis |
| mesh[10].qualifier_ui | Q000473 |
| mesh[10].descriptor_ui | D009205 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pathology |
| mesh[10].descriptor_name | Myocarditis |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D012307 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Risk Factors |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D032921 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Consensus |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006801 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Humans |
| mesh[14].qualifier_ui | Q000009 |
| mesh[14].descriptor_ui | D007167 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | adverse effects |
| mesh[14].descriptor_name | Immunotherapy |
| mesh[15].qualifier_ui | Q000139 |
| mesh[15].descriptor_ui | D009205 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | chemically induced |
| mesh[15].descriptor_name | Myocarditis |
| mesh[16].qualifier_ui | Q000473 |
| mesh[16].descriptor_ui | D009205 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | pathology |
| mesh[16].descriptor_name | Myocarditis |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D012307 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Risk Factors |
| type | article |
| title | Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action |
| biblio.issue | 8 |
| biblio.volume | 23 |
| biblio.last_page | 878 |
| biblio.first_page | 874 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T11491 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9907000064849854 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | CAR-T cell therapy research |
| topics[2].id | https://openalex.org/T11020 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9811000227928162 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immune Cell Function and Interaction |
| is_xpac | False |
| apc_list.value | 3494 |
| apc_list.currency | USD |
| apc_list.value_usd | 3494 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780875844 |
| concepts[0].level | 2 |
| concepts[0].score | 0.853879451751709 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q186235 |
| concepts[0].display_name | Myocarditis |
| concepts[1].id | https://openalex.org/C2776650110 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7006690502166748 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q12891156 |
| concepts[1].display_name | Seriousness |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.6817178726196289 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C197934379 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6532491445541382 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[3].display_name | Adverse effect |
| concepts[4].id | https://openalex.org/C177713679 |
| concepts[4].level | 1 |
| concepts[4].score | 0.53180992603302 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[4].display_name | Intensive care medicine |
| concepts[5].id | https://openalex.org/C2781433595 |
| concepts[5].level | 4 |
| concepts[5].score | 0.4675784409046173 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2459042 |
| concepts[5].display_name | Ipilimumab |
| concepts[6].id | https://openalex.org/C2780851360 |
| concepts[6].level | 4 |
| concepts[6].score | 0.4243316054344177 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q21686041 |
| concepts[6].display_name | Immune checkpoint |
| concepts[7].id | https://openalex.org/C121608353 |
| concepts[7].level | 2 |
| concepts[7].score | 0.39059364795684814 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[7].display_name | Cancer |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.34928712248802185 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C143998085 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3331982493400574 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[9].display_name | Oncology |
| concepts[10].id | https://openalex.org/C2777701055 |
| concepts[10].level | 3 |
| concepts[10].score | 0.2431136965751648 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[10].display_name | Immunotherapy |
| concepts[11].id | https://openalex.org/C17744445 |
| concepts[11].level | 0 |
| concepts[11].score | 0.19662940502166748 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q36442 |
| concepts[11].display_name | Political science |
| concepts[12].id | https://openalex.org/C199539241 |
| concepts[12].level | 1 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7748 |
| concepts[12].display_name | Law |
| keywords[0].id | https://openalex.org/keywords/myocarditis |
| keywords[0].score | 0.853879451751709 |
| keywords[0].display_name | Myocarditis |
| keywords[1].id | https://openalex.org/keywords/seriousness |
| keywords[1].score | 0.7006690502166748 |
| keywords[1].display_name | Seriousness |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.6817178726196289 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/adverse-effect |
| keywords[3].score | 0.6532491445541382 |
| keywords[3].display_name | Adverse effect |
| keywords[4].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[4].score | 0.53180992603302 |
| keywords[4].display_name | Intensive care medicine |
| keywords[5].id | https://openalex.org/keywords/ipilimumab |
| keywords[5].score | 0.4675784409046173 |
| keywords[5].display_name | Ipilimumab |
| keywords[6].id | https://openalex.org/keywords/immune-checkpoint |
| keywords[6].score | 0.4243316054344177 |
| keywords[6].display_name | Immune checkpoint |
| keywords[7].id | https://openalex.org/keywords/cancer |
| keywords[7].score | 0.39059364795684814 |
| keywords[7].display_name | Cancer |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.34928712248802185 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/oncology |
| keywords[9].score | 0.3331982493400574 |
| keywords[9].display_name | Oncology |
| keywords[10].id | https://openalex.org/keywords/immunotherapy |
| keywords[10].score | 0.2431136965751648 |
| keywords[10].display_name | Immunotherapy |
| keywords[11].id | https://openalex.org/keywords/political-science |
| keywords[11].score | 0.19662940502166748 |
| keywords[11].display_name | Political science |
| language | en |
| locations[0].id | doi:10.1634/theoncologist.2018-0157 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S15523509 |
| locations[0].source.issn | 1083-7159, 1549-490X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1083-7159 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | The Oncologist |
| locations[0].source.host_organization | https://openalex.org/P4310316295 |
| locations[0].source.host_organization_name | AlphaMed Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310316295 |
| locations[0].source.host_organization_lineage_names | AlphaMed Press |
| locations[0].license | |
| locations[0].pdf_url | https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0157 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | The Oncologist |
| locations[0].landing_page_url | https://doi.org/10.1634/theoncologist.2018-0157 |
| locations[1].id | pmid:29802220 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | The oncologist |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/29802220 |
| locations[2].id | pmh:oai:escholarship.org:ark:/13030/qt9fw0z96g |
| locations[2].is_oa | False |
| locations[2].source | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | The Oncologist, vol 23, iss 8 |
| locations[2].landing_page_url | https://escholarship.org/uc/item/9fw0z96g |
| locations[3].id | pmh:oai:europepmc.org:5103705 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | http://europepmc.org/pmc/articles/PMC6156187 |
| locations[4].id | pmh:oai:pubmedcentral.nih.gov:6156187 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S2764455111 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | PubMed Central |
| locations[4].source.host_organization | https://openalex.org/I1299303238 |
| locations[4].source.host_organization_name | National Institutes of Health |
| locations[4].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[4].license | |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | Oncologist |
| locations[4].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/6156187 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5087164932 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1513-8833 |
| authorships[0].author.display_name | Tomas G. Neilan |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[0].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, Massachusetts, USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[0].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Massachusetts General Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Tomas G. Neilan |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Massachusetts General Hospital, Boston, Massachusetts, USA |
| authorships[1].author.id | https://openalex.org/A5109982877 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Mace L. Rothenberg |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I180857899 |
| authorships[1].affiliations[0].raw_affiliation_string | Pfizer Inc, New York, New York, USA |
| authorships[1].institutions[0].id | https://openalex.org/I180857899 |
| authorships[1].institutions[0].ror | https://ror.org/01xdqrp08 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I180857899 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Pfizer (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mace L. Rothenberg |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Pfizer Inc, New York, New York, USA |
| authorships[2].author.id | https://openalex.org/A5062916090 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-0056-5437 |
| authorships[2].author.display_name | Laleh Amiri‐Kordestani |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[2].affiliations[0].raw_affiliation_string | Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA |
| authorships[2].institutions[0].id | https://openalex.org/I1333606569 |
| authorships[2].institutions[0].ror | https://ror.org/00yf3tm42 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Center for Drug Evaluation and Research |
| authorships[2].institutions[1].id | https://openalex.org/I1320320070 |
| authorships[2].institutions[1].ror | https://ror.org/034xvzb47 |
| authorships[2].institutions[1].type | government |
| authorships[2].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | United States Food and Drug Administration |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Laleh Amiri-Kordestani |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA |
| authorships[3].author.id | https://openalex.org/A5008479799 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-5344-6645 |
| authorships[3].author.display_name | Ryan J. Sullivan |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[3].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, Massachusetts, USA |
| authorships[3].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[3].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Massachusetts General Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Ryan J. Sullivan |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Massachusetts General Hospital, Boston, Massachusetts, USA |
| authorships[4].author.id | https://openalex.org/A5056374636 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7650-0242 |
| authorships[4].author.display_name | Richard M. Steingart |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[4].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, USA |
| authorships[4].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[4].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Richard M. Steingart |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, New York, New York, USA |
| authorships[5].author.id | https://openalex.org/A5110671457 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | William W. Gregory |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I180857899 |
| authorships[5].affiliations[0].raw_affiliation_string | Pfizer Inc, New York, New York, USA |
| authorships[5].institutions[0].id | https://openalex.org/I180857899 |
| authorships[5].institutions[0].ror | https://ror.org/01xdqrp08 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I180857899 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Pfizer (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | William Gregory |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Pfizer Inc, New York, New York, USA |
| authorships[6].author.id | https://openalex.org/A5051429729 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0126-2718 |
| authorships[6].author.display_name | Hariharan Subramanian |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I180857899 |
| authorships[6].affiliations[0].raw_affiliation_string | Pfizer Inc, New York, New York, USA |
| authorships[6].institutions[0].id | https://openalex.org/I180857899 |
| authorships[6].institutions[0].ror | https://ror.org/01xdqrp08 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I180857899 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Pfizer (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Subramanian Hariharan |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Pfizer Inc, New York, New York, USA |
| authorships[7].author.id | https://openalex.org/A5046388350 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8229-4716 |
| authorships[7].author.display_name | Tarek A. Hammad |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210098679 |
| authorships[7].affiliations[0].raw_affiliation_string | EMD Serono Inc, Billerica, Massachusetts, USA |
| authorships[7].institutions[0].id | https://openalex.org/I4210098679 |
| authorships[7].institutions[0].ror | https://ror.org/010xeam31 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210098679, https://openalex.org/I4210112155 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Ono Pharmaceutical (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Tarek A. Hammad |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | EMD Serono Inc, Billerica, Massachusetts, USA |
| authorships[8].author.id | https://openalex.org/A5031383756 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-9207-3634 |
| authorships[8].author.display_name | JoAnn Lindenfeld |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I200719446 |
| authorships[8].affiliations[0].raw_affiliation_string | Vanderbilt University, Nashville, Tennessee, USA |
| authorships[8].institutions[0].id | https://openalex.org/I200719446 |
| authorships[8].institutions[0].ror | https://ror.org/02vm5rt34 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I200719446 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Vanderbilt University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | JoAnn Lindenfeld |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Vanderbilt University, Nashville, Tennessee, USA |
| authorships[9].author.id | https://openalex.org/A5044115824 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-1108-3967 |
| authorships[9].author.display_name | Martin J. Murphy |
| authorships[9].affiliations[0].raw_affiliation_string | Project Data Sphere, LLC, Cary, North Carolina, USA |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Martin J. Murphy |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Project Data Sphere, LLC, Cary, North Carolina, USA |
| authorships[10].author.id | https://openalex.org/A5019401898 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-5443-4312 |
| authorships[10].author.display_name | Javid J. Moslehi |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I200719446 |
| authorships[10].affiliations[0].raw_affiliation_string | Vanderbilt University, Nashville, Tennessee, USA |
| authorships[10].institutions[0].id | https://openalex.org/I200719446 |
| authorships[10].institutions[0].ror | https://ror.org/02vm5rt34 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I200719446 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Vanderbilt University |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | Javid J. Moslehi |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Vanderbilt University, Nashville, Tennessee, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0157 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W2028614536, https://openalex.org/W2356638506, https://openalex.org/W1991763283, https://openalex.org/W2089959096, https://openalex.org/W1971282566, https://openalex.org/W3166651797, https://openalex.org/W17590606, https://openalex.org/W2276473168, https://openalex.org/W2981745426, https://openalex.org/W4300981098 |
| cited_by_count | 104 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 4 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 5 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 9 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 14 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 26 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 21 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 19 |
| counts_by_year[7].year | 2018 |
| counts_by_year[7].cited_by_count | 6 |
| locations_count | 5 |
| best_oa_location.id | doi:10.1634/theoncologist.2018-0157 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S15523509 |
| best_oa_location.source.issn | 1083-7159, 1549-490X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1083-7159 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | The Oncologist |
| best_oa_location.source.host_organization | https://openalex.org/P4310316295 |
| best_oa_location.source.host_organization_name | AlphaMed Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310316295 |
| best_oa_location.source.host_organization_lineage_names | AlphaMed Press |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0157 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | The Oncologist |
| best_oa_location.landing_page_url | https://doi.org/10.1634/theoncologist.2018-0157 |
| primary_location.id | doi:10.1634/theoncologist.2018-0157 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S15523509 |
| primary_location.source.issn | 1083-7159, 1549-490X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1083-7159 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | The Oncologist |
| primary_location.source.host_organization | https://openalex.org/P4310316295 |
| primary_location.source.host_organization_name | AlphaMed Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310316295 |
| primary_location.source.host_organization_lineage_names | AlphaMed Press |
| primary_location.license | |
| primary_location.pdf_url | https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0157 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | The Oncologist |
| primary_location.landing_page_url | https://doi.org/10.1634/theoncologist.2018-0157 |
| publication_date | 2018-05-25 |
| publication_year | 2018 |
| referenced_works | https://openalex.org/W2783137027, https://openalex.org/W2547310148, https://openalex.org/W2734522096, https://openalex.org/W2768429453, https://openalex.org/W2786816161, https://openalex.org/W2000222100, https://openalex.org/W1992987036, https://openalex.org/W2301851804, https://openalex.org/W2338693579, https://openalex.org/W2412051818, https://openalex.org/W2502471875, https://openalex.org/W2478478625, https://openalex.org/W2466250207, https://openalex.org/W2522075115, https://openalex.org/W2547133566, https://openalex.org/W2566702711, https://openalex.org/W2612667367, https://openalex.org/W2744958889, https://openalex.org/W2746645054, https://openalex.org/W2752571331, https://openalex.org/W2743727543, https://openalex.org/W2767495054, https://openalex.org/W6745459984, https://openalex.org/W2767587838, https://openalex.org/W2778563419, https://openalex.org/W2766590818, https://openalex.org/W2766602219, https://openalex.org/W2597397027, https://openalex.org/W2070825440, https://openalex.org/W2760661635, https://openalex.org/W2339890238, https://openalex.org/W2747440871, https://openalex.org/W2793167197, https://openalex.org/W2789315292, https://openalex.org/W2769632314, https://openalex.org/W6715006712, https://openalex.org/W2774533844, https://openalex.org/W2602017089, https://openalex.org/W2140921081, https://openalex.org/W2489412617, https://openalex.org/W2163036968, https://openalex.org/W1574315642, https://openalex.org/W2135175382, https://openalex.org/W2130852062, https://openalex.org/W2160799564, https://openalex.org/W2789465165, https://openalex.org/W2767726613 |
| referenced_works_count | 47 |
| abstract_inverted_index.a | 86, 115, 126 |
| abstract_inverted_index.In | 170 |
| abstract_inverted_index.an | 26, 51 |
| abstract_inverted_index.as | 50 |
| abstract_inverted_index.at | 100, 125 |
| abstract_inverted_index.be | 99 |
| abstract_inverted_index.by | 129 |
| abstract_inverted_index.in | 58, 188 |
| abstract_inverted_index.is | 69 |
| abstract_inverted_index.of | 16, 18, 30, 66, 72, 82, 92, 118, 185 |
| abstract_inverted_index.on | 134, 146, 156 |
| abstract_inverted_index.to | 13, 89, 141, 151, 164, 181 |
| abstract_inverted_index.we | 173 |
| abstract_inverted_index.15, | 136 |
| abstract_inverted_index.Due | 12 |
| abstract_inverted_index.The | 109 |
| abstract_inverted_index.and | 40, 45, 64, 76, 102, 106, 121, 153, 160, 178 |
| abstract_inverted_index.are | 41 |
| abstract_inverted_index.but | 53 |
| abstract_inverted_index.for | 10 |
| abstract_inverted_index.has | 48 |
| abstract_inverted_index.its | 73 |
| abstract_inverted_index.low | 43, 74 |
| abstract_inverted_index.may | 98 |
| abstract_inverted_index.the | 7, 14, 80, 143, 166, 175, 183 |
| abstract_inverted_index.who | 97 |
| abstract_inverted_index.Data | 131 |
| abstract_inverted_index.LLC, | 133 |
| abstract_inverted_index.This | 138 |
| abstract_inverted_index.been | 38 |
| abstract_inverted_index.data | 155 |
| abstract_inverted_index.have | 5, 37 |
| abstract_inverted_index.side | 28 |
| abstract_inverted_index.task | 162 |
| abstract_inverted_index.this | 93, 157, 171 |
| abstract_inverted_index.were | 25 |
| abstract_inverted_index.with | 61, 190 |
| abstract_inverted_index.2017. | 137 |
| abstract_inverted_index.ICIs, | 19 |
| abstract_inverted_index.ICIs. | 62 |
| abstract_inverted_index.aimed | 140 |
| abstract_inverted_index.close | 165 |
| abstract_inverted_index.early | 104 |
| abstract_inverted_index.gaps. | 169 |
| abstract_inverted_index.grade | 44 |
| abstract_inverted_index.risk, | 101 |
| abstract_inverted_index.share | 154 |
| abstract_inverted_index.steps | 180 |
| abstract_inverted_index.these | 31, 33 |
| abstract_inverted_index.(ICIs) | 4 |
| abstract_inverted_index.Immune | 1 |
| abstract_inverted_index.Safety | 112 |
| abstract_inverted_index.action | 17 |
| abstract_inverted_index.effect | 29 |
| abstract_inverted_index.effort | 88 |
| abstract_inverted_index.enable | 103 |
| abstract_inverted_index.events | 36 |
| abstract_inverted_index.forces | 163 |
| abstract_inverted_index.hosted | 128 |
| abstract_inverted_index.impact | 184 |
| abstract_inverted_index.normal | 23 |
| abstract_inverted_index.tissue | 24 |
| abstract_inverted_index.Project | 130 |
| abstract_inverted_index.Sphere, | 132 |
| abstract_inverted_index.Working | 113 |
| abstract_inverted_index.address | 182 |
| abstract_inverted_index.adverse | 35, 56, 158 |
| abstract_inverted_index.against | 22 |
| abstract_inverted_index.agents; | 32 |
| abstract_inverted_index.because | 71 |
| abstract_inverted_index.cancer. | 11, 191 |
| abstract_inverted_index.collect | 152 |
| abstract_inverted_index.current | 144 |
| abstract_inverted_index.emerged | 49 |
| abstract_inverted_index.meeting | 139 |
| abstract_inverted_index.methods | 150 |
| abstract_inverted_index.protean | 77 |
| abstract_inverted_index.report, | 172 |
| abstract_inverted_index.treated | 60 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.December | 135 |
| abstract_inverted_index.convened | 124 |
| abstract_inverted_index.evaluate | 142 |
| abstract_inverted_index.findings | 177 |
| abstract_inverted_index.identify | 95 |
| abstract_inverted_index.increase | 90 |
| abstract_inverted_index.patients | 59, 96, 189 |
| abstract_inverted_index.proposed | 179 |
| abstract_inverted_index.reaction | 57 |
| abstract_inverted_index.uncommon | 52 |
| abstract_inverted_index.workshop | 127, 176 |
| abstract_inverted_index.Group,” | 114 |
| abstract_inverted_index.Inhibitor | 111 |
| abstract_inverted_index.academic, | 119 |
| abstract_inverted_index.awareness | 91 |
| abstract_inverted_index.committee | 117 |
| abstract_inverted_index.determine | 149 |
| abstract_inverted_index.diagnosis | 105 |
| abstract_inverted_index.establish | 161 |
| abstract_inverted_index.incidence | 75 |
| abstract_inverted_index.industry, | 120 |
| abstract_inverted_index.justifies | 85 |
| abstract_inverted_index.knowledge | 168 |
| abstract_inverted_index.landscape | 9 |
| abstract_inverted_index.mechanism | 15 |
| abstract_inverted_index.partners, | 123 |
| abstract_inverted_index.reaction, | 159 |
| abstract_inverted_index.reactions | 21 |
| abstract_inverted_index.summarize | 174 |
| abstract_inverted_index.syndrome, | 94 |
| abstract_inverted_index.treatment | 8 |
| abstract_inverted_index.typically | 42 |
| abstract_inverted_index.Assessment | 63 |
| abstract_inverted_index.checkpoint | 2 |
| abstract_inverted_index.documented | 39 |
| abstract_inverted_index.identified | 167 |
| abstract_inverted_index.inhibitors | 3 |
| abstract_inverted_index.regulatory | 122 |
| abstract_inverted_index.treatment. | 108 |
| abstract_inverted_index.Myocarditis | 47 |
| abstract_inverted_index.anticipated | 27 |
| abstract_inverted_index.appropriate | 107 |
| abstract_inverted_index.challenging | 70 |
| abstract_inverted_index.coordinated | 87 |
| abstract_inverted_index.information | 145 |
| abstract_inverted_index.manageable. | 46 |
| abstract_inverted_index.myocarditis | 68, 84, 187 |
| abstract_inverted_index.potentially | 54 |
| abstract_inverted_index.seriousness | 81 |
| abstract_inverted_index.transformed | 6 |
| abstract_inverted_index.inflammatory | 20 |
| abstract_inverted_index.myocarditis, | 148 |
| abstract_inverted_index.Nevertheless, | 79 |
| abstract_inverted_index.“Checkpoint | 110 |
| abstract_inverted_index.ICI-associated | 67, 83, 147, 186 |
| abstract_inverted_index.immune-related | 34 |
| abstract_inverted_index.manifestations. | 78 |
| abstract_inverted_index.characterization | 65 |
| abstract_inverted_index.life-threatening | 55 |
| abstract_inverted_index.multidisciplinary | 116 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5087164932 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| corresponding_institution_ids | https://openalex.org/I4210087915 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/17 |
| sustainable_development_goals[0].score | 0.44999998807907104 |
| sustainable_development_goals[0].display_name | Partnerships for the goals |
| citation_normalized_percentile.value | 0.98091931 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |